MacroGenics | MGNX - Assets


MacroGenics reported $318.68M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Amgen USD 96.05B 409M Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Daiichi Sankyo JPY 4.26T 144.08B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Genmab DKK 12.52B 139M Jun/2026
Geron USD 527.11M 8.1M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 318.68M 26.72M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Xencor USD 770.5M 45.54M Sep/2026